Therefore, the primary resistance to Osimertinib reported in this article is extremely complex, including the involvement of multiple genes, missense mutations in NTRK1 and ZRSR2, which would be the first reported drug‐causing factors involved in NSCLC and its mechanism is worth noting. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.